Clélia Coutzac

7PUBLICATIONS
52CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 24, 2026
Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial.

|Jul 24, 2026
Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy.

|Apr 14, 2026
Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP.

Christelle de la Fouchardière, Aziz Zaanan, Aymeric de Montfort

|Oct 30, 2025
Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world study.

Emily Alouani, Julien Taieb, David Tougeron

|Jun 30, 2025
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial.

Edith Borcoman, Bastien Cabarrou, Miguel Francisco

|Apr 23, 2022
A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3.

Christelle de la Fouchardière, Pia Gamradt, Sylvie Chabaud

Pageof 2

Frequent Collaborators

3 joint publications

Samuel Le Sourd

3 joint publications

David Tougeron

2 joint publications

Christelle de la Fouchardière

2 joint publications

Julien Taieb